公开(公告)号：US20190083469A1

公开(公告)日：2019-03-21

申请号：US15741871

申请日：2017-06-09

Applicant: ORYZON GENOMICS, S.A.

Inventor： Tamara MAES ,  Cristina MASCARÒ CRUSAT ,  David ROTLLANT POZO

IPC: A61K31/4245 ,  A61P25/28

Abstract: Provided herein are methods for treating multiple sclerosis using (−) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

公开(公告)号：US20180284095A1

公开(公告)日：2018-10-04

申请号：US15735377

申请日：2016-06-10

Applicant: Oryzon Genomics, S.A.

Inventor： Tamara MAES ,  Cristina MASCARÓ CRUSAT ,  David ROTLLANT POZO

IPC: G01N33/15 ,  A61K31/4245 ,  A61K31/165 ,  A61K31/495 ,  A61K31/40 ,  A61P25/28

Abstract: The invention relates to biomarkers associated with LSD1 inhibitors and uses thereof to assess target engagement and to follow patient response to treatment. The invention further relates to novel therapeutic uses for LSD1 inhibitors based on said biomarkers.

公开(公告)号：US20170209432A1

公开(公告)日：2017-07-27

申请号：US15369003

申请日：2016-12-05

Applicant: ORYZON GENOMICS S.A.

Inventor： Matthew Colin Thor FYFE ,  Tamara MAES ,  Marc MARTINELL PEDEMONTE ,  Inigo TIRAPU FERNANDEZ DE LA CUESTA

IPC: A61K31/495 ,  A61K31/145 ,  A61K31/44 ,  A61K31/40 ,  A61K45/06 ,  A61K31/165

CPC classification number: A61K31/495 ,  A61K31/00 ,  A61K31/135 ,  A61K31/145 ,  A61K31/164 ,  A61K31/165 ,  A61K31/40 ,  A61K31/44 ,  A61K31/4965 ,  A61K45/06 ,  C07C215/64 ,  C07C237/20 ,  C07C311/13 ,  C07D207/14 ,  C07D213/38 ,  C07D241/04

Abstract: The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders.